An effective pill for obesity treatment looks to be within reach. This week, Novo Nordisk announced the results of a Phase III clinical trial testing out an oral version of its in-demand drug semaglutide. The once-daily pill not only substantially outperformed a placebo but did as well as the injectable form of the…
